Cue Biopharma (NASDAQ:CUE) Insider Sells $51,724.20 in Stock

Cue Biopharma, Inc. (NASDAQ:CUE) insider Sumita Ray sold 1,844 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.05, for a total value of $51,724.20. Following the sale, the insider directly owned 116,701 shares of the company’s stock, valued at approximately $3,273,463.05. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sumita Ray also recently made the following trade(s):

• On Thursday, August 13th, Sumita Ray sold 8,829 shares of Cue Biopharma stock. The shares were sold at an average price of $30.09, for a total value of $265,664.61.

Cue Biopharma Stock Performance

Shares of Cue Biopharma stock traded down $0.97 during trading hours on Wednesday, hitting $18.60. The company’s stock had a trading volume of 244,958 shares, compared to its average volume of 475,854. Cue Biopharma, Inc. has a twelve month low of $4.97 and a twelve month high of $45.50. The firm has a fifty day moving average of $27.73 and a 200-day moving average of $72.25. The stock has a market cap of $135.04 million, a price-to-earnings ratio of -0.69 and a beta of 2.62.

Cue Biopharma (NASDAQ:CUE) last issued its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The business had revenue of $7.88 million for the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%. On average, sell-side analysts expect that Cue Biopharma, Inc. will post -21.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC grew its stake in shares of Cue Biopharma by 301.8% in the second quarter. Citadel Advisors LLC now owns 25,633 shares of the company’s stock valued at $809,000 after buying an additional 38,333 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in shares of Cue Biopharma in the 2nd quarter valued at $338,000. Bank of America Corp DE acquired a new position in Cue Biopharma during the 2nd quarter worth about $219,000. ADAR1 Capital Management LLC acquired a new position in Cue Biopharma during the 2nd quarter worth about $1,742,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in Cue Biopharma during the 2nd quarter worth about $83,000. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on CUE. B. Riley Financial assumed coverage on shares of Cue Biopharma in a research note on Friday, September 18th. They set a “buy” rating and a $83.00 target price for the company. Wall Street Zen cut shares of Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 26th. Zacks Research raised shares of Cue Biopharma to a “hold” rating in a research note on Monday, September 21st. Finally, Weiss Ratings downgraded shares of Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $83.00.

About Cue Biopharma

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.